Cspc Pharmaceutical Group Limited · HKEX:1093
Cspc Pharmaceutical — Q3 2025 Earnings Presentation
40 slides from Cspc Pharmaceutical's earnings presentation, November 2025
Slide 1: 2025 Q3 Results Presentation
2025 Q3 Results Presentation Nov. 2025
Slide 2: China's Leading Innovative Pharmaceutical Enterprise
China’s Leading Innovative Pharmaceutical Enterprise R&D Capabilities Manufacturing Capabilities • 10+ Production bases for pharmaceutical products • Nano formulation production capacity of 20M doses/year; Biologics fermentation 8 5 capacity of 250,000L R&D platforms R&D centers located in • Chemica
Slide 3: 2025Q3 Updates
2025Q3 Updates Regulatory Updates Major Clinical Trial Progress 3 new drugs approved: • Enyitan • Shanzeping 52 IND approvals : • China (42) North America (10) • Meiluotai 5 breakthrough therapy designations: • SYS6010 for injection (EGFR ADC) 12 new pivotal clinical trials: • SYS6010 for injection
Slide 4: 2025 - 2026 Data Read-out
2025 - 2026 Data Read-out 2025 2026 (Plan-Updating) • B7H3 ADC - advanced solid tumor - phase I Obesity week ( 2025/11 )： • SYS6010 - data updates for lung cancer, esophageal • JMT206 - ActRIIA/IIB-ORAL (preclinical） squamous cell carcinoma, gastric cancer, etc. • ALK7 SiRNA - Poster (preclinical） •
Slide 5: Remarkable Success of the R&D Pipeline
Remarkable Success of the R&D Pipeline Innovative products launched since 2021 Key Milestones：The year of 2025 provide continuous growth momentum Approved for marketing Amphotericin B liposome DBPR108 Irinotecan liposome 2021-2022 (the U.S.） T2DM 1L Pancreatic cancer Marketing Irinotecan liposome Du
Slide 6: Financial Highlights
01 Financial Highlights
Slide 7: Financial Highlights
Financial Highlights Unit: RMB’ M 1-9/2025 1-9/2024 Change Revenue 19,891 22,686 -12.3% Gross profit 13,049 15,985 -18.4% Gross profit margin 65.6% 70.5% -4.9 pp R&D expenses 4,185 3,880 +7.9% Reported profit attributable to shareholders of the Company 3,511 3,778 -7.1% Underlying profit attributabl
Slide 8: Revenue
Revenue Revenue by product category Revenue by therapeutic area Unit: RMB’ M 1-9/2025 1-9/2024 Change 1-9/2025 1-9/2024 Change Nervous system 5,669 7,234 -21.6% Oncology 1,645 3,809 -56.8% Finished drugs 15,450 18,670 -17.2% Anti-infectives 2,483 3,211 -22.7% Bulk vitamin C 1,788 1,462 +22.3% Cardio
Slide 9: Operating Profit
Operating Profit Unit: RMB’ M 1-9/2025 1-9/2024 1-9/2025 1-9/2024 Change Change OPM OPM Finished drugs 3,234 4,232 -23.6% 20.9% 22.7% -1.8 pp Bulk vitamin C 197 111 +77.9% 11.0% 7.6% +3.4 pp Bulk antibiotics 162 239 -32.2% 13.3% 18.9% -5.6 pp Functional Food and Others 295 235 +25.5% 20.6% 18.2% +2.
Slide 10: Overview of Clinical Development for Key Products
02 Overview of Clinical Development for Key Products
Slide 11: Oncology: Innovative Nano-Formulation Platform, Unlocking the Paclitaxel Market
Oncology: Innovative Nano-Formulation Platform, Unlocking the Paclitaxel Market Indication PhI PhII PhIII NDA Docetaxel for injection (albumin- ≥2L Gastric Cancer （ vs Taxotere） enrolling 2027 bound)-Globally Exclusive ≥3L Pancreatic enrolling Cancer 2026 albumin （ vs Optimal supportive treatment） d
Slide 12: Oncology: HER2 BsAb – Anbenitamab injection
Oncology: HER2 BsAb – Anbenitamab injection Overview of Clinical Development for Anbenitamab Injection Dual blockade of HER2 II and IV epitopes Indication Treatment IND PhI/II PhIII BLA Breast cancer 1L breast cancer Co HB1801 Follow-up 2026 （N=885) vs trastuzumab, pertuzumab + docetaxel albumin Bre
Slide 13: Anbenitamab injection + chemotherapy vs placebo + chemotherapy
Anbenitamab injection + chemotherapy vs placebo + chemotherapy HER2 + Gastric cancer(2L+) interim analysis results of Phase III trial Main results: ※ PFS: 7.1 vs 2.7 mo ※ OS: 19.6 vs 11.5 mo HR 0.25 HR 0.29 ※ ORR：56% vs 11% ※ Grade ≥3TRAEs 60% vs 45% Data cutoff date：2025/4 13
Slide 14: Oncology: HER2 ADC - SYS6091
Oncology: HER2 ADC - SYS6091 Indication Treatment HER2 Status N ORR PFS Glycan-specific conjugation platform All population 46* 63.0% 7.7m 2025 Ovarian Platinum IHC 0 21 52.4% 6.6m ASCO cancer resistance IHC 1- 3+ 18 72.2% 9.4m ASCO Breast ≥ 2L HER2+** 30 73.3% - 2025 cancer ASCO GC/GEJ 27 63.0% 9.6
Slide 15: Oncology: JMT101 (EGFR Monoclonal Antibody)
Oncology: JMT101 (EGFR Monoclonal Antibody) Indication Phase II Phase III Remarks EGFR 20ins NSCLC (1L) JMT101+osimertinib vs Platinum-based chemotherapy 2026 BLA EGFR mutation NSCLC (1L) JMT101+ osimertinib vs osimertinib 2027 BLA High affinity (7 times as much as cetuximab) Advanced colorectal c
Slide 16: JMT101+SG001+ Irinotecan vs Regorafenib
JMT101+SG001+ Irinotecan vs Regorafenib Results of a randomized, controlled, open-label Phase II trial for the treatment of advanced colorectal cancer (3L+) (Arm A, n=36) (Arm B, n=35) (Arm C, n=35) Events, 18 20 28 n/N (%) (50.0) (57.1) (80.0) mPFS, 5.7 7.4 2.9 Mo (95%CI) (3.75, -) (3.91, -) (2.14,
Slide 17: Oncology: SYS6010 EGFR ADC
Oncology: SYS6010 EGFR ADC Indication Treatment PhI PhII PhIII Remarks EGFR 1 SYS6010 vs Platinum- 2L EGFRmut NSCLC 2026 BLA 2 based chemotherapy Phase Ib/III SYS6010+Osimertinib 1L EGFRmut NSCLC Phase Ib 3 vs Osimertinib under follow up 4 EGFR wt NSCLC and other advanced solid SYS6010+SG001 tumors
Slide 18: Oncology: Simmitinib — Entering Pivotal Trial for ESCC
Oncology: Simmitinib — Entering Pivotal Trial for ESCC Simmitinib is a small molecule oral inhibitor targeting FGFR1-3, KDR and CSF-1R Approximately 240,000 new EC cases are reported annually in China, with ESCC accounting for 90% Phase I study of simertinib monotherapy for advanced solid tumors Ind
Slide 19: Immunity: SYHX1901—Covering a Variety of Autoimmune Diseases
Immunity: SYHX1901—Covering a Variety of Autoimmune Diseases Multi-target inhibition JAK1 JAK3 TYK2 Potential Syk inhibitory activity Clear mechanism of action, with multiple Positive results from phase II trial of psoriasis, with all dosage indications being approved for clinical evaluation groups
Slide 20: Immunity: SYS6093 — Covering Asthma Populations Regardless of Phenotype
Immunity: SYS6093 — Covering Asthma Populations Regardless of Phenotype Indication Phase I Phase II Phase III BLA Moderate-to-Severe Phase II finished under planning 2029 Asthma Chronic Rhinosinusitis with Phase II finished 2028 Nasal Polyps COPD Phase II/ III 2032 Registration Category: Target Popu
Slide 21: Immunity: BCMA CAR-T — A New Therapy for Drug-Free Remission
Immunity: BCMA CAR-T — A New Therapy for Drug-Free Remission in Autoimmune Diseases Indication IIT Phase I Phase II IND approval Systemic Lupus Phase I dose escalation Erythematosus 2024/8 + cohort expansion Myasthenia Gravis Phase I dose escalation + cohort expansion 2024/10 Registration Category:
Slide 22: Cardiovascular and Endocrine Metabolism: GLP-1 Series Products
Cardiovascular and Endocrine Metabolism: GLP-1 Series Products Clinical development and layout of GLP-1 series products Indication Phase I Phase II Phase III NDA TG103 (Fc-GLP1) (Class 1) Obesity 2025/9 T2DM 2026 H1 2023.4 TG103 Phase Ia Semaglutide Injection (Class 2.2) Obesity 2025 H2 T2DM 2025/8
Slide 23: Cardiovascular and Endocrine Metabolism: Multi-pronged progress and innovation-driven development
Cardiovascular and endocrine Metabolism: Multi-pronged progress and innovation- driven development JMT206 Best-In-Class ActRIIA/IIB Blocker For Superior Body Composition Management In Combination With GLP-1 RAs CSPC-ALK7— a ALK7 siRNA SYH2082—a Long-acting GLP1R/GIPR Agnoist https://tos.planion.com/
Slide 24: Cardiovascular and Endocrine Metabolism: SiRNA Series Products
Cardiovascular and Endocrine Metabolism: SiRNA Series Products Indication Phase I Phase II Phase III PCSK9 SiRNA Adult primary hypercholesterolemia Expected to launch byend-2025 and mixed dyslipidemia LP（a）SiRNA Hyperlipoprotein A-emia AGT SiRNA hypertension ANGPTL3 SiRNA Dyslipidemia C5 SiRNA Compl
Slide 25: R&D Pipeline
03 R＆D Pipeline
Slide 26: R&D Overview
R&D Overview R&D Centers& Technology Intellectual Science and Technology Projects Projects Platforms Property & Awards • 5 R&D centres located in • 8 national science & technology • 2409 patent applications • 91 national science and China & the U.S. qualifications technology projects • 1040 patents
Slide 27: Innovative R&D Platforms
8 Innovative R&D Platforms Nano- mRNA ADC formulation vaccine siRNA Mitoxantrone Hydrochloride Covid-19 mRNA Liposomes vaccine, VZV mRNA PCSK9 siRNA, EGFR-ADC Albumin-bound docetaxel vaccine and various AGT siRNA ROR1-ADC Irinotecan liposomes preventive and Lp(a) siANA B7H3-ADC
Slide 28: Key Innovative Products in Clinical Stage
Key Innovative Products in Clinical Stage Phase I Phase II Phase II/III Pivotal Trial NDA/BLA Irinotecan liposome NBL-028 NBL-015 NBL-020 JMT106 SYS6002 JMT101 DP303C SYS6010 1L Metastatic CLDN6-CD137 CLDN18.2 mAb TNFR2 BsAb Nectin-4 ADC EGFR mAb HER2 ADC EGFR ADC pancreatic cancer SYS6090 Anbenitam
Slide 29: R&D Pipeline--Biological Agents
R＆D Pipeline--Biological Agents 3 commercialized, 4 BLA filed, 8 under pivotal trial stage, ＞15 under pre-clinical stage —— Including various forms of drugs such as antibody drugs, cell therapies, and Antibody-Drug Conjugates (ADCs) Major Target Type Phase I Phase II Phase II/III NDA/BLA Launch cand
Slide 30: R&D Pipeline--Biological Agents
R＆D Pipeline--Biological Agents Major candidates Target Type Phase I Phase II Phase II/III NDA/BLA Launch JMT103 RANKL mAb Launch: GCTB; Under clinical development: bone metastasis (PhIII)、osteoporosis SYSA1802 PD-1 mAb Launch: Advanced cervical cancer; Under clinical development: IL cervical cancer
Slide 31: R&D Pipeline--New Formulations
R＆D Pipeline--New Formulations 3 commercialized, 4 NDA filed, 2 under pivotal trial stage, ＞5 under clinical development stage ——Including various forms of drugs such as liposomes, albumin and nanocrystals Major candidates Type Phase I Phase II Phase II/III NDA/BLA Launch Mitoxantrone hydrochloride
Slide 32: R&D Pipeline--Small Molecule Drugs
R＆D Pipeline--Small Molecule Drugs 1 commercialized, 2 NDA filed, 7 under pivotal trial stage, ＞ 10 under clinical development stage Major candidates Target Type Phase I Phase II Phase II/III NDA/BLA Launch DBPR108 DPP-4 Small molecule T2DM (approved), T2DM (compound preparations are under research)
Slide 33: Common Generics Launch Plan
Common Generics Launch Plan 20+ generic drugs are expected to be approved during the years 2025-2026; Additionally, approximately 30 projects are currently in the pharmaceutical research phase. 2025 2026 Peramivir Injection Regorafenib tablets Alprazole enteric lansoprazole enteric- Iron sucrose Inj
Slide 34: BD＆ESG
04 BD＆ESG
Slide 35: BD Strategic Layout and Path of Advancement
BD Strategic Layout and Path of Advancement Deepen the BD strategy and build an international BD ecosystem Licence out in 2025 SYS6005 SYH2086 Irinotecan Liposome Injection Strategic collaboration ROR1 ADC GLP-1 Time： 2025.2 Time： 2025.5 Time： 2025.6 Time： 2025.7 Scope: overseas development and Scop
Slide 36: Aim to Become an ESG Leader in Pharmaceutical Industry
Aim to Become an ESG Leader in Pharmaceutical Industry 2024 Key Environmental Protection Data Received MSCI ESG Rating of A for 5 *The emission reduction target is based on the emission in 2017 consecutive years Greenhouse gas emissions per Emission of non-hazardous Discharge of hazardous waste (gen
Slide 37: Appendix: Product Overview
05 Appendix: Product Overview
Slide 38: Finished Drugs Overview by Therapeutic Areas
Finished Drugs Overview by Therapeutic Areas Nervous • Major products: NBP, Mingfule-AIS (recombinant human TNK tissue-type plasminogen system activator for injection), Shuanling, Enliwei (lacosamide injection, lacosamide tablets), Enxi (Pramipexole Dihydrochloride Tablets), Oushuan (paliperidone Ex
Slide 39: Innovation achievements: Overview of Key products
Innovation achievements: Overview of Key products New Formulations and Innovative drugs Biosimilar Drugs NBP Mingfule Jinyouli Duomeisu Duoenyi Butylphthalide Recombinant human TNK PEG-rhG-CSF Doxorubicin Hydrochloride Irinotecan hydrochloride soft capsules and tissue-type plasminogen injection lipo
Slide 40: Thanks!
40 E-mail Address of CSPC IR Team： [email protected] IR official website: Thanks！
CSPC Pharmaceutical Group — Q3 2025 Earnings Presentation on 6ix